Cogent Biosciences, Inc.
COGT
Rank in Stocks
#3330
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Share Price
$30.11
Last synced: 2026-10-19
Market Cap
$5.22B
Change (1 day)
2.00%
Change (1 year)
85.64%
Country
US
Trade Cogent Biosciences, Inc. (COGT)
Category
Healthcare
Stock split history for Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. stock (symbol: COGT) underwent a total of 1 stock splits.
The most recent stock split occurred on Nov 09, 2020.
One COGT share bought prior to Nov 09, 2020 would equal to 0.25 COGT shares today.
The most recent stock split occurred on Nov 09, 2020.
One COGT share bought prior to Nov 09, 2020 would equal to 0.25 COGT shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| 2020-11-09 | 1:4 | x0.25 | x0.25 |
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
